Magnesium treatment increases gut microbiome synthesizing vitamin D and inhibiting colorectal cancer: results from a double-blind precision-based randomized placebo-controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This trial was registered at clinicaltrials.gov as NCT04229992 (https://clinicaltrials.gov/study/NCT04229992?term=NCT04229992&rank=1).

The parent study is registered as NCT03265483, and another relevant study is registered as NCT01105169.

Who Took Part

According to the abstract, 240 participants were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Stool, rectal swabs, and rectal mucosa were collected.

What Was Measured

PubMed files the paper under topics including Gastrointestinal Microbiome, Colorectal Neoplasms, TRPM Cation Channels, Magnesium, Vitamin D, Feces and Genotype.

Author keywords: colorectal cancer, magnesium treatment, precision medicine and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 240 participants.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.